Katherine A High - Net Worth and Insider Trading
Katherine A High Net Worth
The estimated net worth of Katherine A High is at least $24 Million dollars as of 2023-03-28. Katherine A High is the See Remarks of Spark Therapeutics Inc and owns about 210,000 shares of Spark Therapeutics Inc (ONCE) stock worth over $24 Million. Details can be seen in Katherine A High's Latest Holdings Summary section.
Transaction Summary of Katherine A High
Katherine A High Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Katherine A High owns 3 companies in total, including CRISPR Therapeutics AG (CRSP) , Incyte Corp (INCY) , and Spark Therapeutics Inc (ONCE) .
Click here to see the complete history of Katherine A High’s form 4 insider trades.
Insider Ownership Summary of Katherine A High
|Ticker||Comapny||Transaction Date||Type of Owner|
|CRSP||CRISPR Therapeutics AG||2019-06-11||director|
|ONCE||Spark Therapeutics Inc||2019-12-17||director & See Remarks|
Katherine A High Latest Holdings Summary
Katherine A High currently owns a total of 1 stock. Katherine A High owns 210,000 shares of Spark Therapeutics Inc (ONCE) as of November 28, 2017, with a value of $24 Million.
Latest Holdings of Katherine A High
|Ticker||Comapny||Latest Transaction Date||Shares Owned||Current Price ($)||Current Value ($)|
|ONCE||Spark Therapeutics Inc||2017-11-28||210,000||113.57||23,849,700|
Holding Weightings of Katherine A High
Katherine A High Form 4 Trading Tracker
According to the SEC Form 4 filings, Katherine A High has made a total of 0 transactions in Spark Therapeutics Inc (ONCE) over the past 5 years. The most-recent trade in Spark Therapeutics Inc is the sale of 5,000 shares on November 28, 2017, which brought Katherine A High around $356,600.
Insider Trading History of Katherine A High
Katherine A High Trading Performance
Katherine A High Ownership Network
Ownership Network List of Katherine A High
Ownership Network Relation of Katherine A High
Katherine A High Owned Company Details
What does CRISPR Therapeutics AG do?
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Who are the key executives at CRISPR Therapeutics AG?
Katherine A High is the director of CRISPR Therapeutics AG. Other key executives at CRISPR Therapeutics AG include Chief Medical Officer Phuong Khanh Morrow , Chief Financial Officer Brendan Smith , and Chief Business Officer Lawrence Otto Klein .
CRISPR Therapeutics AG (CRSP) Insider Trades Summary
Over the past 18 months, Katherine A High made no insider transaction in CRISPR Therapeutics AG (CRSP). Other recent insider transactions involving CRISPR Therapeutics AG (CRSP) include a net sale of 225,000 shares made by Samarth Kulkarni ,
In summary, during the past 3 months, insiders sold 50,000 shares of CRISPR Therapeutics AG (CRSP) in total and bought 0 shares, with a net sale of 50,000 shares. During the past 18 months, 225,000 shares of CRISPR Therapeutics AG (CRSP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 225,000 shares.
CRISPR Therapeutics AG (CRSP)'s detailed insider trading history can be found in Insider Trading Tracker table.
CRISPR Therapeutics AG Insider Transactions
Katherine A High Mailing Address
Above is the net worth, insider trading, and ownership report for Katherine A High. You might contact Katherine A High via mailing address: 3737 Market Street, Suite 1300, Philadelphia Pa 19104.